Female sexual disorder(FSD). Female sexual arousal disorder
Conditions
Interventions
Intervention 1: Intervention group: 37patient will be received Crucuma zedoaria capsule ( herbal medicine from white turmeric) manufactured by Danesh Bonyan Shafangar Nazari Co. QID for 4 weeks. Inter
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 35 Years
Inclusion criteria
Inclusion criteria: Healthy menstruating women with regular menstrual cycles(between 28-34 days) between 18-35 years of age Being married Documented clinical diagnosis of FSD based on FSFI score. Body mass index (BMI)=LT30. Suffering from FSD for more than 6 months. Nomal sexual function in partner Agree not to use any other form of herbal or hormonal therapies for treatment of sexual dysfunction Women using non hormonal method of contraception to prevent pregnancy.
Exclusion criteria
Exclusion criteria: Pregnancy or attempting to conceive. Breastfeeding within 3 months prior to the study. Having marital discord. Receiving androgen therapy within 3 months of recruitment. Consuming any form of hormonal contraceptive. Consuming drug with a potential to cause sexual dysfunction (such as selective serotonin reuptake inhibitors, tricyclic antidepressants, antihypertensive drugs, etc.) and receiving stations or other drugs known to impact on steroid hormone levels and women who are taking anti-coagulant or anti-platelet drugs in the previous 3 months. Subjects with serious medical conditions such as history of breast, endometrial or other gynecological cancer at any time before study or other cancer within the last 5 years, hypertension, diabetes, tuberculosis, lupus, cardiovascular disease, thrombo-embolic disorders, neurologic or psychiatric disease were also excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Female sexual disorder score based on female sexual functin index( FSFI) questionnaire. Timepoint: Before and after the end of the 4-week period of treatment. Method of measurement: female sexual function index( FSFI).;Measurment of testosterone level. Timepoint: Measuring testosterone level before the study and then during the folliculate phase of their next menstural cycle on the day of 7 to 9 after the end of study. Method of measurement: Chemiluminesence Immunoassay (cl). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHoda Nasr Fard Jahromi
Shiraz University of Medical Sciences
Outcome results
None listed